VIRATECH CORP. RELEASES WHITE PAPER ON CANCER.IM        

STOCKTON, CALIFORNIA/February 21, 2013 / Newswire/ -- Viratech Corp. (OTC: VIRA), the first open source biotech research social network platform, announced today that, in keeping with its commitment to full transparency and disclosure, as well as its dedication to deliver the world’s first experienced-based social network resource site for cancer patients, survivors, advocates, and volunteers, it has released the white paper, titled “The Power of Cancer.im.” The white paper, which can be found on Viratech’s web site, outlines Cancer.im's function which is designed to improve the lives of cancer patients by providing them with a support network that will connect them to friends, supporters, advocates, doctors, and resources that can increase patient confidence and contribute to a higher quality of life.

“I am excited about this…because every cancer survivor has a unique story to tell. The hindsight and experiences of those who have already ‘been there’ are invaluable to patients currently battling the disease. Members of the Cancer.im network can find survivors who have lived through a specific type and stage of cancer. They can learn from these survivors what to expect,” states Dr. Kevin Buckman, CEO of Viratech.

About Cancer.im

Through its experience-based search engine and technology, Cancer.im's goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others. Cancer.im’s mission is to empower every cancer patient with the ability to research their disease and to find, organize, and manage their own cancer support network at no charge to them. The goal of these support networks is to assist the patient in conserving needed energy by reducing the burden associated with their own daily trials and tribulations. Cancer.im will strive to convert this saved energy into a higher level of patient activity and a stronger determination to fight their disease.

In addition, Cancer.im is seeking new cancer researchers who wish to leverage its intellectual property and social network platform for the purpose of creating new distribution and engagement channels.

About Viratech Corp.

Based in Stockton, California, Viratech Corp., which just announced its acquisition of Cancer.im, http://www.youtube.com/watch?v=dz1tHRb3wvU, has created an open source biotech research and development platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology. This has been made possible by leveraging social collaboration in a way that allows new biotech ventures the ability to protect their intellectual property, then simultaneously allowing those same ventures the ability to promote and crowdsource their development.  

Forward-Looking Statements

This press release includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward-looking statements whether as a result of new information, future events or otherwise.

Contact: Kevin Buckman MD

Viratech, Corp.

http://viratech.org

Email Contact: info@viratech.org

Tel: 209 477 3030